IDH1 and glioblastoma: We find that the Agilent GBM pattern predicts survival statistically better than and independent of the best other indicators, i.e., the patient's age and tumor's grade49 and survival and response to treatments, i.e., chemotherapy and radiation, better than the existing tests, i.e., for MGMT promoter methylation and IDH1 mutation.50,51